Member Info for ShearClass

Where on earth did you read that? They can’t raise capital below the nominal value of the shares though, so would have to subdivide them before any raise etc. Keeping an eye here but nothing more for now.

“$100 million revenue from the Chinese deal is still very much on the cards.”

You can’t be serious surely? If that was anywhere near being true why wouldn’t the Chinese customer just buy ENET?

This is a £4.5m micro cap with no cash, consequently they have no bargaining power or ability to invest in developing their product. That is the bigger issue here, how much ground will be lost given that R&D spend will have been cut to close to zero?

Haha, oh trying to live up to a nickname are we? Is that what you’ve been trying to do over the last year + by continuously ramping targets of £1/2 a share? How’s that worked out for you?

Traceylied, I have to ask what is your connection with ENET? 128 posts in the last month, all on this BB, you do realise other shares exist?

This is a pathetic amount to raise & suggests they couldn’t attract any serious money - otherwise why wouldn’t II’s have piled in on that discount? My guess is that Levi is the problem, he didn’t want to dilute his holding & has likely been in denial all year about the need to do so. Otherwise why not raise £700k at 40p instead of going through such a pallava?

It’s not visibly dropped because the book value of Verici was only $2m, so around £1.6m. 59.4m shares issued at that validation equate to an effective ex dividend adjustment of 2.7p, which is nothing given the current spread.

They’ve done the spin off very cleverly in my opinion; leave it until the IPO and the Verici valuation could / will be £40-60m & the ex div impact on RENX would have been significant (as per EKF when they span off RENX back in October 18).

I’ve been critical of AVCT’s management in the past as I feel they’ve always looked out for institutions & high net worth investors at the expense of PI’s (see 2 x placings in April right before material news & the now infamous one at £1.20). However, putting all that to one side, I don’t think there has ever been a better time to own shares here. IMO the involvement of Cytiva will mean the rapid POC test makes it to market, as they have managed with SONA. It’s also clear that PCR isn’t suitable for long term mass testing - I certainly don’t fancy a swab being stuffed up my nose. I’d say the odds of an RNS update next week are high, could be any day as the last 3 have been released in Tue / Wed / Thur.

Short term target of £2.50 upon successful test specs - volume will be off the charts on a SONA type RNS.

Wow that Motley Fool article is so stupid, what on earth are they do trying to achieve using the 2019 revenue as a price to sales multiple?! I’d say it’s deliberately misleading to be honest - applying that type of prior year analysis to any share that’s changed materially would produce a ridiculous result. They should be embarrassed to publish such utter tripe.

Given the slight delay to reporting June figures, it seems more likely we’ll get a full YTD trading update than a simple revenue total. Would be great to get confirmation of their EBITDA etc.

They're desperately trying to hold the 10p line, but it's going to have to give soon - then into proper breakout territory...

They would have 100% RNS’d any sales orders received, as they haven’t released anything it’s safe to assume there have been no orders to date. Clearly discussions will be taking place, but until orders are formally announced they are not worth anything!

Not wanting to crash the free money party, but where are the commercials here? There hasn’t been one RNS that has flagged anything at all from a financial point of view other than a £100k order from Senegal?! If that’s the materiality level then good luck justifying an £80m market cap...

Huge volume in the end, looks like we have two II's exchanging shares, with several 100k buys matched off against 25k sells. £5.5m traded in total, certainly more to it than PI's. So much newsflow that could land any day, so I expect the SP growth to continue for a long while yet!

Yep it’s gradually gaining awareness, still pretty undiscovered though. This weeks RNS was fantastic, both acquiring new IP & partnering with big pharma to expand the scope of KidneyIntelX, the future is very exciting. Strange that Dr Kildare / Bernardo hasn’t commented on it?

Yet more positive news today;

“NEW YORK, July 1, 2020 - Renalytix AI plc ( LSE: RENX), an artificial intelligence -enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs , announces results of a clinical validation study have undergone peer-review and have been accepted for publication in the American Society of Nephrology Journal, Kidney360.”

More fantastic news this morning;

Prof. Matthias Kretzler, Professor of Computational Medicine & Bioinformatics and Internal Medicine at UM stated : "The primary aim of our research has always been the translation of findings to clinical practice in order to improve patient care and kidney health. The C-PROBE cohort was established with the express aim of enabling this translation to take place. We are very excited to partner with RenalytixAI in this endeavor and firmly believe that KidneyIntelX platform is an ideal vehicle to integrate the results of our work on uEGF with other biomarkers, bioinformatics and clinical research, with the goal of providing new, powerful solutions in managing CKD."

Fergus Fleming, Chief Technology Officer and Co-founder of RenalytixAI stated: "These partnerships are both significant developments for our technology development roadmap and strategic objectives for the company. Access to these data sets and samples potentially demonstrates the value of the KidneyIntelX platform and our ability to collaborate with leaders in discovery, clinical care and novel therapeutic development for kidney disease. We expect that gaining access to this clinical trial data, biomarker technology and the C-PROBE cohort will be key milestones in the development of expanded indications for KidneyIntelX, potentially allowing us to offer solutions to a greater number of the approximately 37 million patients currently estimated to have CKD."

Already widely reported yesterday, I.e.

https://www.theguardian.com/business/2020/jun/26/wirecard-uk-ordered-to-freeze-customer-funds-by-finance-regulator

“Travel money providers FairFX and Asda Money said holders of their prepaid foreign currency cards were not able to use them. FairFX said it was looking for a solution for customers, but their money was safe.”

“ShearClass - why would DC take £210k of his loan to the company in shares?”

Because he has no other choice? He’s already getting repaid via his inflated salary anyway.

I don’t understand how anyone can defend a man who takes a £400k salary in a £9m market cap company that needs to place / take exorbitant loans on a regular basis.

He’s living the dream at the expense of shareholders, just as he did at his previous listed entity parallel media.

Does the following sound familiar?

https://www.google.co.uk/amp/s/www.independent.co.uk/news/business/news/when-golf-is-just-a-good-investment-spoiled-56400.html%3famp

“Investors, whose shares are now worth just 3.25p each compared with a peak of over 160p, have been left dazed and confused. How can it be that its prospectus - supported by undertakings from Mr O'Brien and Mr Morgan that it was correct, and backed by a clean audit statement from BDO Stoy Hayward - failed to highlight problems that would undermine the whole group? Mr O'Brien blames David Ciclitira, Parallel's chairman.”

So far LVCG has fallen from a high of £1 to 10p today, when will the merry go round end?

Monday 29th for the results.

As a reminder from the Jan trading update;

“Equals Group plc, the e-banking and international payments group, announces the following trading update related to the full year 2019.

Full year turnover for the Group was GBP2.91 billion, an increase of 23% on the prior year (2018: GBP2.36 billion). Revenues for the full year 2019 were up approximately 20% over 2018, with revenues in the second half of the year comfortably exceeding the first half, reflecting the continued underlying growth of the business. Despite significant investment in branding, marketing and senior organisational hires to support future growth, adjusted EBITDA is expected to be 30% higher than 2018 and therefore increasing by a greater percentage than revenue. Cash at bank and liquidity providers, less customer liabilities, amounted to GBP16.4 million at 31st December 2019, putting the Group in a strong position to pursue further growth opportunities in 2020. These results have been achieved against a backdrop of challenging market conditions, caused by political and economic uncertainties which resulted in record-low currency volatilities.

The Group's stated strategy to focus on Corporate/B2B customers, which represent more profitable relationships with greater longevity than retail consumers, was successfully delivered with 52% of Group revenue generated from B2B during the year, compared to 37% in 2018. Furthermore, approximately 71% of Group turnover was derived from Corporate/B2B in 2019, up from 57% in 2018, which points to stronger B2B revenue growth in 2020. This shift towards B2B has been driven by investments into the Group, providing Equals with substantial product advantages over its competitors. These include the Equals Spend corporate expenses platform, which integrates bank-grade capabilities and connectivity to payments networks both in the UK and overseas. The assembled product suite increasingly enables Equals to access a greater share of B2B customer wallets and to service larger corporate customers as well as SME size businesses.“

Share price was 80p when they released this & it fell to 60p during the week after as it was a slight miss versus aggressive forecasts. Very happy to buy at 33p now, especially knowing they had £16.4m in cash at year end.

As a reminder to any newbies, Ciclitera took £400k + in salary last year and £500k the year before, so his commitment is minimal - the pittance raised in the placing today will likely just about cover his 2020 salary!

Because the site is knackered, there’s been missing trade data all year!